*2.1.3 Sintilimab*

Sintilimab is an anti-PD-1 antibody developed by Innovent Biologics, Suzhou, China. Shi et al*.* reported it exhibits comparable activity to nivolumab and pembrolizumab in patients with r/r cHL [89]. In their single-arm, multicenter, phase II trial (NCT03114683), 6-months PFS was 77.6%, and 74 of 92 fully analyzed patients (80.4%) achieved an objective response. Among those with objective responses, 31 (34%) had CR and 43 (47%) had PR. As for AE, 89 (93%) of 96 patients demonstrated treatment-related AE, including 17 (18%) with grade 3 or 4 and 11 (11%) with serious treatment-related AE (all expected).
